CAJ | 학술논문

目的红细胞免疫低下是尿毒症维持性血液透析患者并发肿瘤的主要原因之一,而氧化应激是严重影响尿毒症维持性血液透析患者生存质量及引发各种并发症的主要原因.通过探讨血液透析患者红细胞免疫低下及高氧化应激状态的特点,观察中药“复方黄芪附子汤”(芪附汤)对患者红细胞CD58、CD59及氧化应激指标的调节作用.方法检测维持性血液透析患者应用“芪附汤”前(用药前组)、后(用药后组)CD58、CD59、超氧化物歧化酶(SOD)、丙二醛(MDA)的浓度,并与同期大连大学附属中山医院体检中心的健康人20名(对照组)的上述指标进行对比.结果用药前、服用“芪附汤”12 d后及对照组CD58[(38.02±8.98)、(47.39±7.78)％与(59.10 ±4.59)％；F =4.506,P=0.000]、CD59[(62.69±20.84)、(80.95±20.42)％与(193.86±19.87)％;F=239.347,P=0.000]、SOD[(68.09±11.86)、(78.73 ±10.58)、(111.09± 16.61) kU/L;F=21.318,P=0.000]、MDA[(5.98 ±2.06)、(4.54±0.62)、(3.03±1.10) μmol/L;F =55.359,P=0.000]比较,差异均有统计学意义；用药前CD58、CD59、SOD浓度较对照组明显降低,MDA明显升高,差异均有统计学意义(P均＜0.01)；服用“复方黄芪附子汤”12 d后,CD58、CD59、SOD较用药前明显升高,MDA较用药前明显降低,差异均有统计学意义(P＜0.01或P＜0.05).结论血液透析患者红细胞表面受体CD58、CD59表达力降低,氧化应激指标SOD明显降低,MDA明显增高,“复方黄芪附子汤”能显著提高维持性血液透析患者的红细胞CD58、CD59浓度,改善患者的氧化应激状态.
목적 홍세포면역저하시뇨독증유지성혈액투석환자병발종류적주요원인지일,이양화응격시엄중영향뇨독증유지성혈액투석환자생존질량급인발각충병발증적주요원인.통과탐토혈액투석환자홍세포면역저하급고양화응격상태적특점,관찰중약“복방황기부자탕”(기부탕)대환자홍세포CD58、CD59급양화응격지표적조절작용.방법 검측유지성혈액투석환자응용“기부탕”전(용약전조)、후(용약후조)CD58、CD59、초양화물기화매(SOD)、병이철(MDA)적농도,병여동기대련대학부속중산의원체검중심적건강인20명(대조조)적상술지표진행대비.결과 용약전、복용“기부탕”12 d후급대조조CD58[(38.02±8.98)、(47.39±7.78)％여(59.10 ±4.59)％；F =4.506,P=0.000]、CD59[(62.69±20.84)、(80.95±20.42)％여(193.86±19.87)％;F=239.347,P=0.000]、SOD[(68.09±11.86)、(78.73 ±10.58)、(111.09± 16.61) kU/L;F=21.318,P=0.000]、MDA[(5.98 ±2.06)、(4.54±0.62)、(3.03±1.10) μmol/L;F =55.359,P=0.000]비교,차이균유통계학의의；용약전CD58、CD59、SOD농도교대조조명현강저,MDA명현승고,차이균유통계학의의(P균＜0.01)；복용“복방황기부자탕”12 d후,CD58、CD59、SOD교용약전명현승고,MDA교용약전명현강저,차이균유통계학의의(P＜0.01혹P＜0.05).결론 혈액투석환자홍세포표면수체CD58、CD59표체력강저,양화응격지표SOD명현강저,MDA명현증고,“복방황기부자탕”능현저제고유지성혈액투석환자적홍세포CD58、CD59농도,개선환자적양화응격상태.
Objective The immune hypofunction of the red blood cell on maintenance hemodialysis patients is one main reason of tumor,and oxidative stress is proved to be involved in decrease of existence quality and the occurrence of various complications of patients with hemodialysis.To investigate the status of erythrocyte immune and high oxidative stress of the hemodialysis patients,as well as the effect of Huangqifuzitang on immune function of red blood cell and oxidative stress in patients with hemodialysis.Methods Twenty healthy people were chosen as control group,and 20 patients were selected as the treatment group.CD58,CD59,superoxide dismutase(SOD),malonaldehyde(MDA) were measured before hemodialysis and after 12 days administration of Huangqifuzitang in the treatment group,and compared with those of the control group.Results There was significant difference between before and after taking Huangqifuzitang in treatment group and control group in terms of CD58 ((38.02 ±8.98) vs.(47.39 ±7.78) vs.(59.10±4.59),F=4.506,P=0.000),CD59 ((62.69 ± 20.84) vs.(80.95 ± 20.42) vs.(193.86 ± 19.87) ; F =239.347,P =0.000),SOD ((68.09 ± 11.86) vs.(78.73±10.58) vs.(111.09±16.61) kU/L;F=21.318,P=0.000),MDA((5.98±2.06) vs.(4.54 ±0.62) vs.(3.03 ± 1.10) μmoL/L;F =55.359,P =0.000) levels.Before taking Huangqifuzitang,the concentration of CD58,CD59 and SOD in treatment group was significant decreased compared with control group,but MDA significant increased,and there was significant difference (P ＜ 0.01).After 12 days administration of Huangqifuzitang in the treatment group,the concentration of CD58,CD59 and SOD was significant increased compared with before taking Huangqifuzitang,but MDA significant significant decreased,and there was significant difference (P ＜ 0.01 or P ＜ 0.05) Conclusion The red blood cell surface receptors CD58,CD59 decreased and oxidative stress index SOD decreased significantly,MDA increased significantly in hemodialysis patients.Huangqifuzitang was proved to be with the ability of enhancing the immune of red bloodCD58,CD59 and decreasing the oxidative stress level in patients with hemodialysis.